Bruce Schnepp, PhD

Bruce brings more than 20 years of experience developing viral vector technologies with an emphasis on adeno-associated virus vectors. Prior to Interius, he served as Senior Director, Technology Development, at Kriya Therapeutics, where he was responsible for vector design and assay development. Previously, Bruce held key scientific roles at Limelight Bio, where he led a team of scientists developing both AAV-mediated and nonviral therapeutics for genetic diseases, and at the Children’s Hospital of Philadelphia, where he was involved in the preclinical design and development of the first-in-human study that used a recombinant AAV vector to deliver a gene for a monoclonal antibody to block HIV infection.

Bruce received his PhD in molecular genetics from Ohio State University and completed his postdoctoral work at Nationwide Children’s Hospital in Columbus, Ohio. He received his undergraduate degree in biology from Purdue University.